<html>
  <head>
    <title></title>
    <!-- Licensed to: Broadridge Financial Soultions, Inc.
         Document created using EDGARfilings PROfile 7.1.0.0
         Copyright 1995 - 2020 Broadridge -->
  </head>
<body style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left; color: #000000;" bgcolor="#ffffff">
  <div>
    <div style="text-align: center; font-weight: bold;">
      <hr style="border: none; border-bottom: 1px solid black; border-top: 4px solid black; height: 10px; color: #ffffff; background-color: #ffffff; margin-left: auto; margin-right: auto;" align="center">As filed with the Securities and Exchange Commission
      on August 28, 2020</div>
    <div><br>
    </div>
    <div style="text-align: right; font-weight: bold;">Registration No. 333-</div>
    <div style="font-size: 14pt;"><br>
    </div>
    <div style="text-align: center; font-family: 'Times New Roman',Times,serif; font-size: 14pt; font-weight: bold;">UNITED STATES</div>
    <div style="text-align: center; font-family: 'Times New Roman',Times,serif; font-size: 14pt; font-weight: bold;">SECURITIES AND EXCHANGE COMMISSION</div>
    <div style="text-align: center; font-family: 'Times New Roman',Times,serif; font-size: 12pt; font-weight: bold;">Washington, D.C. 20549</div>
    <div><br>
    </div>
    <div style="text-align: center; font-family: 'Times New Roman',Times,serif; font-size: 18pt; font-weight: bold;">FORM S-8</div>
    <div style="text-align: center; font-family: 'Times New Roman',Times,serif; font-size: 18pt; font-weight: bold;">REGISTRATION STATEMENT</div>
    <div style="text-align: center; font-family: 'Times New Roman',Times,serif; font-size: 12pt; font-style: italic; font-weight: bold;">UNDER</div>
    <div style="text-align: center; font-family: 'Times New Roman',Times,serif; font-size: 12pt; font-style: italic; font-weight: bold;">THE SECURITIES ACT OF 1933</div>
    <div style="text-align: center; font-style: italic; font-weight: bold;"> <br>
    </div>
    <div style="text-align: center; font-family: 'Times New Roman',Times,serif; font-size: 24pt; font-weight: bold;">Bionano Genomics, Inc.</div>
    <div style="text-align: center; font-weight: bold;">(Exact name of registrant as specified in its charter)</div>
    <div><br>
    </div>
    <table style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;" id="z76dc27b356d944549bc65d403159db3f" border="0" cellpadding="0" cellspacing="0">

        <tr>
          <td style="width: 50%; vertical-align: top;">
            <div style="text-align: center; font-weight: bold;">Delaware</div>
          </td>
          <td style="width: 50%; vertical-align: top;">
            <div style="text-align: center; font-weight: bold;">26-1756290</div>
          </td>
        </tr>
        <tr>
          <td style="width: 50%; vertical-align: top;">
            <div style="text-align: center; font-weight: bold;">(State or other jurisdiction of</div>
            <div style="text-align: center; font-weight: bold;">incorporation or organization)</div>
          </td>
          <td style="width: 50%; vertical-align: top;">
            <div style="text-align: center; font-weight: bold;">(I.R.S. Employer</div>
            <div style="text-align: center; font-weight: bold;">Identification No.)</div>
          </td>
        </tr>
        <tr>
          <td style="width: 50%; vertical-align: middle;">&#160;</td>
          <td style="width: 50%; vertical-align: middle;">&#160;</td>
        </tr>
        <tr>
          <td style="width: 50%; vertical-align: top;">
            <div style="text-align: center; font-weight: bold;">9540 Towne Centre Drive, Suite 100</div>
            <div style="text-align: center; font-weight: bold;">San Diego, California</div>
          </td>
          <td style="width: 50%; vertical-align: bottom;">
            <div style="text-align: center; font-weight: bold;">92121</div>
          </td>
        </tr>
        <tr>
          <td style="width: 50%; vertical-align: top;">
            <div style="text-align: center; font-weight: bold;">(Address of Principal Executive Offices)</div>
          </td>
          <td style="width: 50%; vertical-align: top;">
            <div style="text-align: center; font-weight: bold;">(Zip Code)</div>
          </td>
        </tr>

    </table>
    <div><br>
    </div>
    <div style="text-align: center; font-weight: bold;">Bionano Genomics, Inc. 2020 Inducement Plan</div>
    <div style="text-align: center; font-weight: bold;">&#160;(Full titles of the plans)</div>
    <div><br>
    </div>
    <div style="text-align: center; font-weight: bold;">R. Erik Holmlin, Ph.D.</div>
    <div style="text-align: center; font-weight: bold;">President and Chief Executive Officer</div>
    <div style="text-align: center; font-weight: bold;">Bionano Genomics, Inc.</div>
    <div style="text-align: center; font-weight: bold;">9540 Towne Centre Drive, Suite 100</div>
    <div style="text-align: center; font-weight: bold;">San Diego, California 92121</div>
    <div style="text-align: center; font-weight: bold;">(858) 888-7600</div>
    <div style="text-align: center; font-weight: bold;">(Name, address, including zip code, and telephone number, including area code, of agent for service)</div>
    <div><br>
    </div>
    <div style="text-align: center; font-style: italic; font-weight: bold;">Copies to:</div>
    <div><br>
    </div>
    <table style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;" id="z1744f228fc7841338b480a5dc0e4da4d" border="0" cellpadding="0" cellspacing="0">

        <tr>
          <td style="width: 50%; vertical-align: top;">
            <div style="text-align: center; font-weight: bold;">Thomas A. Coll, Esq.</div>
            <div style="text-align: center; font-weight: bold;">James C. Pennington, Esq.</div>
            <div style="text-align: center; font-weight: bold;">Cooley LLP</div>
            <div style="text-align: center; font-weight: bold;">4401 Eastgate Mall</div>
            <div style="text-align: center; font-weight: bold;">San Diego, California 92121</div>
            <div style="text-align: center; font-weight: bold;">(858) 550-6000</div>
          </td>
          <td style="width: 50%; vertical-align: top;">
            <div style="text-align: center; font-weight: bold;">R. Erik Holmlin, Ph.D.</div>
            <div style="text-align: center; font-weight: bold;">President and Chief Executive Officer</div>
            <div style="text-align: center; font-weight: bold;">Bionano Genomics, Inc.</div>
            <div style="text-align: center; font-weight: bold;">9540 Towne Centre Drive, Suite 100</div>
            <div style="text-align: center; font-weight: bold;">San Diego, California 92121</div>
            <div style="text-align: center; font-weight: bold;">(858) 888-7600</div>
          </td>
        </tr>

    </table>
    <div><br>
    </div>
    <div>Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of &#8220;large accelerated filer,&#8221; &#8220;accelerated
      filer,&#8221; &#8220;smaller reporting company,&#8221; and &#8220;emerging growth company&#8221; in Rule 12b-2 of the Exchange Act.</div>
    <div><br>
    </div>
    <table style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;" id="za31c37da094f4fc090b3d1396651de07" cellpadding="0" cellspacing="0">

        <tr>
          <td style="width: 42.46%; vertical-align: bottom;">
            <div>Large accelerated filer &#9744;</div>
          </td>
          <td style="width: 57.54%; vertical-align: bottom;">
            <div>Accelerated filer &#9744;</div>
          </td>
        </tr>
        <tr>
          <td style="width: 42.46%; vertical-align: middle;">&#160;</td>
          <td style="width: 57.54%; vertical-align: top;">&#160;</td>
        </tr>
        <tr>
          <td style="width: 42.46%; vertical-align: bottom;">
            <div>Non-accelerated filer &#9746;</div>
          </td>
          <td style="width: 57.54%; vertical-align: bottom;">
            <div>Smaller reporting company &#9746;</div>
          </td>
        </tr>
        <tr>
          <td style="width: 42.46%; vertical-align: middle;">&#160;</td>
          <td style="width: 57.54%; vertical-align: top;">&#160;</td>
        </tr>
        <tr>
          <td style="width: 42.46%; vertical-align: bottom;">&#160;</td>
          <td style="width: 57.54%; vertical-align: bottom;">
            <div>Emerging growth company &#9746;</div>
          </td>
        </tr>

    </table>
    <div><br>
    </div>
    <div>If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the
      Securities Act. &#9744;</div>
    <div><br>
    </div>
    <div style="text-align: center; font-weight: bold;">CALCULATION OF REGISTRATION FEE</div>
    <table style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;" id="zf027d70474f2456994005419178c7851" border="0" cellpadding="0" cellspacing="0">

        <tr>
          <td style="width: 20%; vertical-align: bottom; border-top: 2px solid rgb(0, 0, 0); border-right: 2px solid rgb(0, 0, 0);">
            <div style="text-align: center; font-weight: bold;">Title of Securities to be Registered</div>
          </td>
          <td style="width: 20%; vertical-align: bottom; border-top: 2px solid rgb(0, 0, 0); border-right: 2px solid rgb(0, 0, 0);" nowrap="nowrap">
            <div style="text-align: center; font-weight: bold;">Amount to be</div>
            <div style="text-align: center; font-weight: bold;">Registered<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">(1)</sup></div>
          </td>
          <td style="width: 20%; vertical-align: bottom; border-top: 2px solid rgb(0, 0, 0); border-right: 2px solid rgb(0, 0, 0);" nowrap="nowrap">
            <div style="text-align: center; font-weight: bold;">Proposed Maximum</div>
            <div style="text-align: center; font-weight: bold;">Offering Price per</div>
            <div style="text-align: center; font-weight: bold;">Share</div>
          </td>
          <td style="width: 20%; vertical-align: bottom; border-top: 2px solid rgb(0, 0, 0); border-right: 2px solid rgb(0, 0, 0);" nowrap="nowrap">
            <div style="text-align: center; font-weight: bold;">Proposed Maximum</div>
            <div style="text-align: center; font-weight: bold;">Aggregate</div>
            <div style="text-align: center; font-weight: bold;">Offering Price</div>
          </td>
          <td style="width: 20%; vertical-align: bottom; border-top: 2px solid rgb(0, 0, 0);" nowrap="nowrap">
            <div style="text-align: center;"><font style="font-weight: bold;"> <br>
              </font></div>
            <div style="text-align: center;"><font style="font-weight: bold;">Amount of</font></div>
            <div style="text-align: center;"><font style="font-weight: bold;"></font><font style="font-weight: bold;">Registration Fee</font></div>
          </td>
        </tr>
        <tr>
          <td style="width: 20%; vertical-align: top; border-top: 2px solid rgb(0, 0, 0); border-bottom: 4px double rgb(0, 0, 0); border-right: 2px solid rgb(0, 0, 0);">
            <div style="text-indent: -10pt; margin-left: 10pt;">Common Stock, par value $0.0001 per share</div>
          </td>
          <td style="width: 20%; vertical-align: bottom; border-top: 2px solid rgb(0, 0, 0); border-bottom: 4px double rgb(0, 0, 0); border-right: 2px solid rgb(0, 0, 0);" nowrap="nowrap">
            <div style="text-align: center;">2,100,000<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">(2)</sup></div>
          </td>
          <td style="width: 20%; vertical-align: bottom; border-top: 2px solid rgb(0, 0, 0); border-bottom: 4px double rgb(0, 0, 0); border-right: 2px solid rgb(0, 0, 0);" nowrap="nowrap">
            <div style="text-align: center;">$0.63<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">(3)</sup></div>
          </td>
          <td style="width: 20%; vertical-align: bottom; border-top: 2px solid rgb(0, 0, 0); border-bottom: 4px double rgb(0, 0, 0); border-right: 2px solid rgb(0, 0, 0);" nowrap="nowrap">
            <div style="text-align: center;">$1,323,000<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">(3)</sup></div>
          </td>
          <td style="width: 20%; vertical-align: bottom; border-top: 2px solid rgb(0, 0, 0); border-bottom: 4px double rgb(0, 0, 0);" nowrap="nowrap">
            <div style="text-align: center;">$171.73</div>
          </td>
        </tr>

    </table>
    <div><br>
    </div>
    <table style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;" border="0" cellpadding="0" cellspacing="0">

        <tr>
          <td style="width: 5%; vertical-align: top;">
            <div>(1)</div>
          </td>
          <td style="vertical-align: top; width: 95%;">
            <div>Pursuant to Rule 416(a) under the Securities Act of 1933, as amended (the &#8220;<font style="font-weight: bold; font-style: italic;">Securities Act</font>&#8221;), this Registration Statement shall also cover any additional shares of common stock,
              par value $0.0001 per share (&#8220;<font style="font-weight: bold; font-style: italic;">Common Stock</font>&#8221;), of Bionano Genomics, Inc. (the &#8220;<font style="font-weight: bold; font-style: italic;">Registrant</font>&#8221;) that become issuable under the
              Registrant&#8217;s 2020 Inducement Plan (the &#8220;<font style="font-weight: bold; font-style: italic;">Inducement Plan</font>&#8221;) by reason of any stock dividend, stock split, recapitalization or any other similar transaction effected without receipt of
              consideration which results in an increase in the number of outstanding shares of Common Stock.</div>
          </td>
        </tr>
        <tr>
          <td style="width: 5%; vertical-align: top;">
            <div>(2)</div>
          </td>
          <td style="vertical-align: top; width: 95%;">
            <div>Represents shares of Common Stock reserved for issuance under the Inducement Plan.</div>
          </td>
        </tr>
        <tr>
          <td style="width: 5%; vertical-align: top;">
            <div>(3)</div>
          </td>
          <td style="vertical-align: top; width: 95%;">
            <div>This estimate is made pursuant to Rule 457(h)(1) and Rule 457(c) of the Securities Act solely for purposes of calculating the registration fee. The price per share and aggregate offering price are based upon the average of the high and low
              prices of the Common Stock on August 27, 2020, as reported on the Nasdaq Capital Market.</div>
          </td>
        </tr>

    </table>
    <div>
      <hr style="border: none; border-bottom: 4px solid black; border-top: 1px solid black; height: 10px; color: #ffffff; background-color: #ffffff; text-align: center; margin-left: auto; margin-right: auto;" align="center"></div>
    <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" id="DSPFPageBreakArea">
      <div style="page-break-after:always;" id="DSPFPageBreak">
        <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" noshade="noshade"></div>
    </div>
    <div style="text-align: center; font-weight: bold;">PART I</div>
    <div><br>
    </div>
    <div style="text-align: center; font-weight: bold;">INFORMATION REQUIRED IN THE SECTION 10(A) PROSPECTUS</div>
    <div><br>
    </div>
    <div>The information called for by Part I of Form S-8 is omitted from this Registration Statement in accordance with Rule 428 of the Securities Act and the instructions to Form S-8. In accordance with the rules and regulations of the Securities and
      Exchange Commission (the &#8220;<font style="font-weight: bold; font-style: italic;">Commission</font>&#8221;) and the instructions to Form S-8, such documents are not being filed with the Commission either as part of this Registration Statement or as
      prospectuses or prospectus supplements pursuant to Rule 424.</div>
    <div><br>
    </div>
    <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" id="DSPFPageBreakArea">
      <div style="page-break-after:always;" id="DSPFPageBreak">
        <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" noshade="noshade"></div>
    </div>
    <div style="text-align: center; font-weight: bold;">PART II</div>
    <div><br>
    </div>
    <div style="text-align: center; font-weight: bold;">INFORMATION REQUIRED IN THE REGISTRATION STATEMENT</div>
    <div><br>
    </div>
    <div><font style="font-weight: bold;">ITEM 3.</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-weight: bold;">INCORPORATION OF DOCUMENTS BY REFERENCE.</font></div>
    <div><br>
    </div>
    <div>The following documents filed by the Registrant with the Commission are incorporated by reference into this Registration Statement:</div>
    <div><br>
    </div>
    <div><font style="font-weight: bold;">(a)</font> The Registrant&#8217;s Annual Report on Form 10-K for the fiscal year ended December 31, 2019 (the &#8220;<font style="font-weight: bold; font-style: italic;">Annual Report</font>&#8221;), filed with the Commission on <a href="http://www.sec.gov/Archives/edgar/data/1411690/000141169020000006/bngo10k-20191231.htm">March 10, 2020</a>.</div>
    <div><br>
    </div>
    <div><font style="font-weight: bold;">(b)</font> the description of the Registrant&#8217;s Common Stock that is contained in a registration statement on Form 8-A filed on <a href="http://www.sec.gov/Archives/edgar/data/1411690/000119312518251675/d610675d8a12ba.htm">August 17, 2018</a> (File No. 001-38613) under the Securities Exchange Act of 1934, as amended (the &#8220;<font style="font-weight: bold; font-style: italic;">Exchange


        Act</font>&#8221;), including any amendment or report filed for the purpose of updating such description, including Exhibit 4.16 to the Registrant&#8217;s Annual Report; and</div>
    <div><br>
    </div>
    <div><font style="font-weight: bold;">(c)</font> all other reports and documents subsequently filed by the Registrant pursuant to Sections 13(a), 13(c), 14 and 15(d) of the Exchange Act (other than Current Reports furnished under Item 2.02 or Item 7.01
      of Form 8-K and exhibits furnished on such form that relate to such items) on or after the date of this Registration Statement and prior to the filing of a post-effective amendment to this Registration Statement that indicates that all securities
      offered have been sold or that deregisters all securities then remaining unsold, shall be deemed to be incorporated by reference herein and to be a part of this Registration Statement from the date of the filing of such reports and documents. Any
      statement contained in a document incorporated or deemed to be incorporated by reference herein shall be deemed to be modified or superseded for purposes of this Registration Statement to the extent that a statement contained herein or in any
      subsequently filed document that also is deemed to be incorporated by reference herein modifies or supersedes such statement. Any such statement so modified or superseded shall not be deemed, except as so modified or superseded, to constitute a part
      of this Registration Statement.</div>
    <div><br>
    </div>
    <div><font style="font-weight: bold;">ITEM 4.</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-weight: bold;">DESCRIPTION OF SECURITIES.</font></div>
    <div><br>
    </div>
    <div>Not applicable.</div>
    <div><br>
    </div>
    <div><font style="font-weight: bold;">ITEM 5.</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-weight: bold;">INTERESTS OF NAMED EXPERTS AND COUNSEL.</font></div>
    <div><br>
    </div>
    <div>Not applicable.</div>
    <div><br>
    </div>
    <div><font style="font-weight: bold;">ITEM 6.</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-weight: bold;">INDEMNIFICATION OF DIRECTORS AND OFFICERS.</font></div>
    <div><br>
    </div>
    <div>Section 145 of the Delaware General Corporation Law authorizes a court to award, or a corporation&#8217;s board of directors to grant, indemnity to directors and officers in terms sufficiently broad to permit such indemnification under certain
      circumstances for liabilities, including reimbursement for expenses incurred, arising under the Securities Act. The Registrant&#8217;s amended and restated certificate of incorporation that will be in effect following the closing of the initial public
      offering permits indemnification of our directors, officers and other agents to the maximum extent permitted by the Delaware General Corporation Law, and the Registrant&#8217;s amended and restated bylaws that will be in effect following the closing of the
      initial public offering provide that the Registrant will indemnify its directors and executive officers and permit the Registrant to indemnify its other officers, employees and other agents, in each case to the maximum extent permitted by the
      Delaware General Corporation Law.</div>
    <div><br>
    </div>
    <div>The Registrant has entered into indemnification agreements with its directors and officers, whereby it has agreed to indemnify its directors and officers to the fullest extent permitted by law, including indemnification against expenses and
      liabilities incurred in legal proceedings to which the director or officer was, or is threatened to be made, a party by reason of the fact that such director or officer is or was a director, officer, employee or agent of the Registrant, provided that
      such director or officer acted in good faith and in a manner that the director or officer reasonably believed to be in, or not opposed to, the best interest of the Registrant. At present, there is no pending litigation or proceeding involving a
      director or officer of the Registrant regarding which indemnification is sought, nor is the registrant aware of any threatened litigation that may result in claims for indemnification.</div>
    <div><br>
    </div>
    <div>The Registrant maintains insurance policies that indemnify its directors and officers against various liabilities arising under the Securities Act and the Exchange Act that might be incurred by any director or officer in his or her capacity as
      such.</div>
    <div><br>
    </div>
    <div><font style="font-weight: bold;">ITEM 7.</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-weight: bold;">EXEMPTION FROM REGISTRATION CLAIMED.</font></div>
    <div><br>
    </div>
    <div>Not applicable.</div>
    <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" id="DSPFPageBreakArea">
      <div style="page-break-after:always;" id="DSPFPageBreak">
        <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" noshade="noshade"></div>
    </div>
    <div><font style="font-weight: bold;">ITEM 8.</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-weight: bold;">EXHIBITS.</font></div>
    <div><br>
    </div>
    <table style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;" id="z748d34e7bd684380b79490a3cf902b1c" cellpadding="0" cellspacing="0">

        <tr>
          <td style="width: 10%; vertical-align: bottom;">
            <div style="font-weight: bold;">Exhibit Number</div>
          </td>
          <td style="width: 90%; vertical-align: bottom;">
            <div style="text-align: center; font-weight: bold;">Description</div>
          </td>
        </tr>
        <tr>
          <td style="width: 10%; vertical-align: top;">
            <div><a href="http://www.sec.gov/Archives/edgar/data/1411690/000119312518257763/d607608dex31.htm">4.1</a><sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">(1)</sup></div>
          </td>
          <td style="width: 90%; vertical-align: top;">
            <div>Amended and Restated Certificate of Incorporation of the Registrant.</div>
          </td>
        </tr>
        <tr>
          <td style="width: 10%; vertical-align: top;">
            <div><a href="http://www.sec.gov/Archives/edgar/data/1411690/000119312518257763/d607608dex32.htm">4.2</a><sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">(1)</sup></div>
          </td>
          <td style="width: 90%; vertical-align: top;">
            <div>Amended and Restated Bylaws of the Registrant.</div>
          </td>
        </tr>
        <tr>
          <td style="width: 10%; vertical-align: top;">
            <div><a href="http://www.sec.gov/Archives/edgar/data/1411690/000119312518219135/d782664dex41.htm">4.3</a><sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">(2)</sup></div>
          </td>
          <td style="width: 90%; vertical-align: top;">
            <div>Form of Common Stock Certificate of the Registrant.</div>
          </td>
        </tr>
        <tr>
          <td style="width: 10%; vertical-align: top;">
            <div><a href="nt10014149x5_ex5-1.htm">5.1</a></div>
          </td>
          <td style="width: 90%; vertical-align: top;">
            <div>Opinion of Cooley LLP.</div>
          </td>
        </tr>
        <tr>
          <td style="width: 10%; vertical-align: top;">
            <div><a href="nt10014149x5_ex23-1.htm">23.1</a></div>
          </td>
          <td style="width: 90%; vertical-align: top;">
            <div>Consent of Independent Registered Public Accounting Firm.</div>
          </td>
        </tr>
        <tr>
          <td style="width: 10%; vertical-align: top;">
            <div><a href="nt10014149x5_ex5-1.htm">23.2</a></div>
          </td>
          <td style="width: 90%; vertical-align: top;">
            <div>Consent of Cooley LLP. Reference is made to Exhibit 5.1.</div>
          </td>
        </tr>
        <tr>
          <td style="width: 10%; vertical-align: top;">
            <div><a href="#SIGNATURES">24.1</a></div>
          </td>
          <td style="width: 90%; vertical-align: top;">
            <div>Power of Attorney. Reference is made to the signature page hereto.</div>
          </td>
        </tr>
        <tr>
          <td style="width: 10%; vertical-align: top;">
            <div><a href="http://www.sec.gov/Archives/edgar/data/1411690/000114036120018910/brhc10014594_ex10-1.htm">99.1</a><sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">(3)</sup></div>
          </td>
          <td style="width: 90%; vertical-align: top;">
            <div>Bionano Genomics, Inc. 2020 Inducement Plan.</div>
          </td>
        </tr>
        <tr>
          <td style="width: 10%; vertical-align: top;">
            <div><a href="http://www.sec.gov/Archives/edgar/data/1411690/000114036120018910/brhc10014594_ex10-2.htm">99.2</a><sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">(3)</sup></div>
          </td>
          <td style="width: 90%; vertical-align: top;">
            <div>Form of Stock Option Grant Notice and Stock Option Agreement under the Bionano Genomics, Inc. 2020 Inducement Plan.</div>
          </td>
        </tr>

    </table>
    <div><br>
    </div>
    <table style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;" id="zdbf24052c42447f5acd9b34226df1ff4" cellpadding="0" cellspacing="0">

        <tr>
          <td style="width: 3.54%; vertical-align: top;">
            <div><sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">(1)</sup></div>
          </td>
          <td style="width: 96.46%; vertical-align: top;">
            <div>Incorporated by reference to the Registrant&#8217;s Current Report on Form 8-K, filed with the SEC on August 24, 2018.</div>
          </td>
        </tr>
        <tr>
          <td style="width: 3.54%; vertical-align: top;">
            <div><sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">(2)</sup></div>
          </td>
          <td style="width: 96.46%; vertical-align: top;">
            <div>Incorporated by reference to the Registrant&#8217;s Registration Statement on Form S-1 (File No. 333-225970), as amended.</div>
          </td>
        </tr>
        <tr>
          <td style="width: 3.54%; vertical-align: top;">
            <div><sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">(3)</sup></div>
          </td>
          <td style="width: 96.46%; vertical-align: top;">
            <div>Incorporated by reference to the Registrant&#8217;s Current Report on Form 8-K, filed with the SEC on August 24, 2020.</div>
          </td>
        </tr>

    </table>
    <div><br>
    </div>
    <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" id="DSPFPageBreakArea">
      <div style="page-break-after:always;" id="DSPFPageBreak">
        <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" noshade="noshade"></div>
    </div>
    <div><font style="font-weight: bold;">ITEM 9.</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-weight: bold;">UNDERTAKINGS.</font></div>
    <div><br>
    </div>
    <div>A. The undersigned Registrant hereby undertakes:</div>
    <div><br>
    </div>
    <div>(1) To file, during any period in which offers or sales are being made, a post-effective amendment to this Registration Statement:</div>
    <div><br>
    </div>
    <div style="text-indent: 36pt;">(i) To include any prospectus required by Section 10(a)(3) of the Securities Act;</div>
    <div><br>
    </div>
    <div style="text-indent: 36pt;">(ii) To reflect in the prospectus any facts or events arising after the effective date of the Registration Statement (or the most recent post-effective amendment thereof) which, individually or in the aggregate,
      represent a fundamental change in the information set forth in the Registration Statement. Notwithstanding the foregoing, any increase or decrease in volume of securities offered (if the total dollar value of securities offered would not exceed that
      which was registered) and any deviation from the low or high end of the estimated maximum offering range may be reflected in the form of prospectus filed with the Commission pursuant to Rule 424(b) if, in the aggregate, the changes in volume and
      price represent no more than a 20% change in the maximum aggregate offering price set forth in the &#8220;Calculation of Registration Fee&#8221; table in the effective Registration Statement; and</div>
    <div><br>
    </div>
    <div style="text-indent: 36pt;">(iii) To include any material information with respect to the plan of distribution not previously disclosed in the Registration Statement or any material change to such information in the Registration Statement.</div>
    <div><br>
    </div>
    <div><font style="font-style: italic;">Provided, however</font>, that paragraphs (A)(1)(i) and (A)(1)(ii) do not apply if the information required to be included in a post-effective amendment by those paragraphs is contained in reports filed with or
      furnished to the Commission by the Registrant pursuant to Section 13 or Section 15(d) of the Exchange Act that are incorporated by reference in the Registration Statement.</div>
    <div><br>
    </div>
    <div>(2) That, for the purpose of determining any liability under the Securities Act, each such post-effective amendment shall be deemed to be a new registration statement relating to the securities offered herein, and the offering of such securities
      at that time shall be deemed to be the initial bona fide offering thereof.</div>
    <div><br>
    </div>
    <div>(3) To remove from registration by means of a post-effective amendment any of the securities being registered which remain unsold at the termination of the offering.</div>
    <div><br>
    </div>
    <div>(4) That, for the purpose of determining liability of the Registrant under the Securities Act to any purchaser in the initial distribution of the securities, the undersigned Registrant undertakes that in a primary offering of securities of the
      undersigned Registrant pursuant to this registration statement, regardless of the underwriting method used to sell the securities to the purchaser, if the securities are offered or sold to such purchaser by means of any of the following
      communications, the undersigned Registrant will be a seller to the purchaser and will be considered to offer or sell such securities to such purchaser:</div>
    <div><br>
    </div>
    <div style="text-indent: 36pt;">(i) Any preliminary prospectus or prospectus of the undersigned Registrant relating to the offering required to be filed pursuant to Rule 424;</div>
    <div><br>
    </div>
    <div style="text-indent: 36pt;">(ii) Any free writing prospectus relating to the offering prepared by or on behalf of the undersigned Registrant or used or referred to by the undersigned Registrant;</div>
    <div><br>
    </div>
    <div style="text-indent: 36pt;">(iii) The portion of any other free writing prospectus relating to the offering containing material information about the undersigned Registrant or its securities provided by or on behalf of the undersigned Registrant;
      and</div>
    <div><br>
    </div>
    <div style="text-indent: 36pt;">(iv) Any other communication that is an offer in the offering made by the undersigned Registrant to the purchaser.</div>
    <div><br>
    </div>
    <div>B. The undersigned Registrant hereby undertakes that, for purposes of determining any liability under the Securities Act, each filing of the Registrant&#8217;s annual report pursuant to Section 13(a) or Section 15(d) of the Exchange Act (and, where
      applicable, each filing of an employee benefit plan&#8217;s annual report pursuant to Section 15(d) of the Exchange Act) that is incorporated by reference in the Registration Statement shall be deemed to be a new registration statement relating to the
      securities offered herein, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof.</div>
    <div><br>
    </div>
    <div>C. Insofar as indemnification for liabilities arising under the Securities Act may be permitted to directors, officers and controlling persons of the Registrant pursuant to the foregoing provisions, or otherwise, the Registrant has been advised
      that in the opinion of the Commission such indemnification is against public policy as expressed in the Securities Act and is, therefore, unenforceable. In the event that a claim for indemnification against such liabilities (other than the payment by
      the Registrant of expenses incurred or paid by a director, officer or controlling person of the Registrant in the successful defense of any action, suit or proceeding) is asserted by such director, officer or controlling person in connection with the
      securities being registered, the Registrant will, unless in the opinion of its counsel the matter has been settled by controlling precedent, submit to a court of appropriate jurisdiction the question whether such indemnification by it is against
      public policy as expressed in the Securities Act and will be governed by the final adjudication of such issue.</div>
    <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" id="DSPFPageBreakArea">
      <div style="page-break-after:always;" id="DSPFPageBreak">
        <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" noshade="noshade"></div>
    </div>
    <div style="text-align: center; font-weight: bold;"><a name="SIGNATURES"><!--Anchor--></a>SIGNATURES</div>
    <div><br>
    </div>
    <div>Pursuant to the requirements of the Securities Act of 1933, as amended, the Registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused this Registration Statement
      to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of San Diego, State of California, on August 28, 2020.</div>
    <div><br>
    </div>
    <table style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;" id="zcbbdf13dad84482291318e4fb6140cad" border="0" cellpadding="0" cellspacing="0">

        <tr>
          <td style="width: 50%; vertical-align: top;">&#160;</td>
          <td colspan="2" style="vertical-align: top;">
            <div style="font-weight: bold;">BIONANO GENOMICS, INC.</div>
          </td>
        </tr>
        <tr>
          <td style="width: 50%; vertical-align: top;">&#160;</td>
          <td style="width: 5%; vertical-align: middle;">&#160;</td>
          <td style="width: 45%; vertical-align: middle;">&#160;</td>
        </tr>
        <tr>
          <td style="width: 50%; vertical-align: top;">&#160;</td>
          <td style="width: 5%; vertical-align: top;">
            <div>By:</div>
          </td>
          <td style="width: 45%; vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0);">
            <div>
              <div>/s/ R. Erik Holmlin, Ph.D.</div>
            </div>
          </td>
        </tr>
        <tr>
          <td style="width: 50%; vertical-align: top;">&#160;</td>
          <td style="width: 5%; vertical-align: top;">&#160;</td>
          <td style="width: 45%; vertical-align: bottom;">
            <div>R. Erik Holmlin, Ph.D.</div>
          </td>
        </tr>
        <tr>
          <td style="width: 50%; vertical-align: top;">&#160;</td>
          <td style="width: 5%; vertical-align: top;">&#160;</td>
          <td style="width: 45%; vertical-align: bottom;">
            <div style="font-style: italic;">President and Chief Executive Officer</div>
          </td>
        </tr>

    </table>
    <div><br>
    </div>
    <div style="text-align: center; font-weight: bold;">POWER OF ATTORNEY</div>
    <div><br>
    </div>
    <div>KNOW ALL BY THESE PRESENTS, that each person whose signature appears below constitutes and appoints R. Erik Holmlin, Ph.D. as his or her true and lawful attorney-in-fact and agent, with the full power of substitution, for him or her and in his or
      her name, place or stead, in any and all capacities, to sign any and all amendments to this Registration Statement (including post-effective amendments), and to file the same, with exhibits thereto and other documents in connection therewith, with
      the Securities and Exchange Commission, granting unto said attorney-in-fact and agent full power and authority to do and perform each and every act and thing requisite and necessary to be done in and about the premises, as fully to all intents and
      purposes as he or she might or could do in person, hereby ratifying and confirming all that said attorney-in-fact and agent, or his substitute or substitutes, may lawfully do or cause to be done by virtue hereof.</div>
    <div><br>
    </div>
    <div>Pursuant to the requirements of the Securities Act of 1933, as amended, this Registration Statement has been signed by the following persons in the capacities and on the dates indicated.</div>
    <div><br>
    </div>
    <table style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;" id="za391f5e63e924e23a65471abd043f3ec" border="0" cellpadding="0" cellspacing="0">

        <tr>
          <td style="width: 31.58%; vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0);">
            <div style="text-align: center; font-weight: bold;">Signature</div>
          </td>
          <td style="width: 1.32%; vertical-align: middle; padding-bottom: 2px;">
            <div>&#8203;</div>
          </td>
          <td style="width: 42.11%; vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0);">
            <div style="text-align: center; font-weight: bold;">Title</div>
          </td>
          <td style="width: 1.32%; vertical-align: middle; padding-bottom: 2px;">
            <div>&#8203;</div>
          </td>
          <td style="width: 23.68%; vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0);">
            <div style="text-align: center; font-weight: bold;">Date</div>
          </td>
        </tr>
        <tr>
          <td style="width: 31.58%; vertical-align: top;">&#160;</td>
          <td style="width: 1.32%; vertical-align: middle;">
            <div>&#8203;</div>
          </td>
          <td style="width: 42.11%; vertical-align: bottom;">&#160;</td>
          <td style="width: 1.32%; vertical-align: middle;">
            <div>&#8203;</div>
          </td>
          <td style="width: 23.68%; vertical-align: bottom;">&#160;</td>
        </tr>
        <tr>
          <td style="width: 31.58%; vertical-align: top; border-bottom: 2px solid rgb(0, 0, 0);">
            <div style="text-align: center;">/s/ R. Erik Holmlin, Ph.D.</div>
          </td>
          <td style="width: 1.32%; vertical-align: middle; padding-bottom: 2px;">
            <div>&#8203;</div>
          </td>
          <td rowspan="2" style="width: 42.11%; vertical-align: middle; padding-bottom: 2px; text-align: center;">
            <div style="font-family: 'Times New Roman',Times,serif;">Chief Executive Officer and Director</div>
            <div style="font-family: 'Times New Roman',Times,serif; font-style: italic;">(Principal Executive and Financial Officer)</div>
          </td>
          <td rowspan="2" style="width: 1.32%; vertical-align: middle; padding-bottom: 2px;">
            <div>&#8203;</div>
          </td>
          <td style="width: 23.68%; vertical-align: top; padding-bottom: 2px;">
            <div style="text-align: center;">August 28, 2020</div>
          </td>
        </tr>
        <tr>
          <td style="width: 31.58%; vertical-align: top;">
            <div style="text-align: center;">R. Erik Holmlin, Ph.D.</div>
          </td>
          <td style="width: 1.32%; vertical-align: middle;">
            <div>&#8203;</div>
          </td>
          <td style="width: 23.68%; vertical-align: top;">&#160;</td>
        </tr>
        <tr>
          <td style="width: 31.58%; vertical-align: top;">&#160;</td>
          <td style="width: 1.32%; vertical-align: middle;">
            <div>&#8203;</div>
          </td>
          <td style="width: 42.11%; vertical-align: top;">&#160;</td>
          <td style="width: 1.32%; vertical-align: middle;">
            <div>&#8203;</div>
          </td>
          <td style="width: 23.68%; vertical-align: top;">&#160;</td>
        </tr>
        <tr>
          <td style="width: 31.58%; vertical-align: top; border-bottom: 2px solid rgb(0, 0, 0);">
            <div style="text-align: center;">/s/ Mark Adamchak</div>
          </td>
          <td style="width: 1.32%; vertical-align: middle; padding-bottom: 2px;">
            <div>&#8203;</div>
          </td>
          <td rowspan="2" style="width: 42.11%; vertical-align: middle; padding-bottom: 2px; text-align: center;">
            <div style="font-family: 'Times New Roman',Times,serif;">Controller</div>
            <div style="font-family: 'Times New Roman',Times,serif; font-style: italic;">(Principal Accounting Officer)</div>
          </td>
          <td rowspan="2" style="width: 1.32%; vertical-align: middle; padding-bottom: 2px;">
            <div>&#8203;</div>
          </td>
          <td style="width: 23.68%; vertical-align: top; padding-bottom: 2px;">
            <div style="text-align: center;">August 28, 2020</div>
          </td>
        </tr>
        <tr>
          <td style="width: 31.58%; vertical-align: top;">
            <div style="text-align: center;">Mark Adamchak</div>
          </td>
          <td style="width: 1.32%; vertical-align: middle;">
            <div>&#8203;</div>
          </td>
          <td style="width: 23.68%; vertical-align: top;">&#160;</td>
        </tr>
        <tr>
          <td style="width: 31.58%; vertical-align: top;">&#160;</td>
          <td style="width: 1.32%; vertical-align: middle;">
            <div>&#8203;</div>
          </td>
          <td style="width: 42.11%; vertical-align: top;">&#160;</td>
          <td style="width: 1.32%; vertical-align: middle;">
            <div>&#8203;</div>
          </td>
          <td style="width: 23.68%; vertical-align: top;">&#160;</td>
        </tr>
        <tr>
          <td style="width: 31.58%; vertical-align: top; border-bottom: 2px solid rgb(0, 0, 0);">
            <div style="text-align: center;">/s/ David L. Barker, Ph.D.</div>
          </td>
          <td style="width: 1.32%; vertical-align: middle; padding-bottom: 2px;">
            <div>&#8203;</div>
          </td>
          <td style="width: 42.11%; vertical-align: top; padding-bottom: 2px;">
            <div style="text-align: center;">Director</div>
          </td>
          <td style="width: 1.32%; vertical-align: middle; padding-bottom: 2px;">
            <div>&#8203;</div>
          </td>
          <td style="width: 23.68%; vertical-align: top; padding-bottom: 2px;">
            <div style="text-align: center;">August 28, 2020</div>
          </td>
        </tr>
        <tr>
          <td style="width: 31.58%; vertical-align: top;">
            <div style="text-align: center;">David L. Barker, Ph.D.</div>
          </td>
          <td style="width: 1.32%; vertical-align: middle;">
            <div>&#8203;</div>
          </td>
          <td style="width: 42.11%; vertical-align: top;">&#160;</td>
          <td style="width: 1.32%; vertical-align: middle;">
            <div>&#8203;</div>
          </td>
          <td style="width: 23.68%; vertical-align: top;">&#160;</td>
        </tr>
        <tr>
          <td style="width: 31.58%; vertical-align: top;">&#160;</td>
          <td style="width: 1.32%; vertical-align: middle;">
            <div>&#8203;</div>
          </td>
          <td style="width: 42.11%; vertical-align: top;">&#160;</td>
          <td style="width: 1.32%; vertical-align: middle;">
            <div>&#8203;</div>
          </td>
          <td style="width: 23.68%; vertical-align: top;">&#160;</td>
        </tr>
        <tr>
          <td style="width: 31.58%; vertical-align: top; border-bottom: 2px solid rgb(0, 0, 0);">
            <div style="text-align: center;">/s/ Yvonne Linney, Ph.D.</div>
          </td>
          <td style="width: 1.32%; vertical-align: middle; padding-bottom: 2px;">
            <div>&#8203;</div>
          </td>
          <td style="width: 42.11%; vertical-align: top; padding-bottom: 2px;">
            <div style="text-align: center;">Director</div>
          </td>
          <td style="width: 1.32%; vertical-align: middle; padding-bottom: 2px;">
            <div>&#8203;</div>
          </td>
          <td style="width: 23.68%; vertical-align: top; padding-bottom: 2px;">
            <div style="text-align: center;">August 28, 2020</div>
          </td>
        </tr>
        <tr>
          <td style="width: 31.58%; vertical-align: top;">
            <div style="text-align: center;">Yvonne Linney, Ph.D.</div>
          </td>
          <td style="width: 1.32%; vertical-align: middle;">
            <div>&#8203;</div>
          </td>
          <td style="width: 42.11%; vertical-align: top;">&#160;</td>
          <td style="width: 1.32%; vertical-align: middle;">
            <div>&#8203;</div>
          </td>
          <td style="width: 23.68%; vertical-align: top;">&#160;</td>
        </tr>
        <tr>
          <td style="width: 31.58%; vertical-align: top;">&#160;</td>
          <td style="width: 1.32%; vertical-align: middle;">
            <div>&#8203;</div>
          </td>
          <td style="width: 42.11%; vertical-align: top;">&#160;</td>
          <td style="width: 1.32%; vertical-align: middle;">
            <div>&#8203;</div>
          </td>
          <td style="width: 23.68%; vertical-align: top;">&#160;</td>
        </tr>
        <tr>
          <td style="width: 31.58%; vertical-align: top; border-bottom: 2px solid rgb(0, 0, 0);">
            <div style="text-align: center;">/s/ Albert A. Luderer, Ph.D.</div>
          </td>
          <td style="width: 1.32%; vertical-align: middle; padding-bottom: 2px;">
            <div>&#8203;</div>
          </td>
          <td style="width: 42.11%; vertical-align: top; padding-bottom: 2px;">
            <div style="text-align: center;">Director</div>
          </td>
          <td style="width: 1.32%; vertical-align: middle; padding-bottom: 2px;">
            <div>&#8203;</div>
          </td>
          <td style="width: 23.68%; vertical-align: top; padding-bottom: 2px;">
            <div style="text-align: center;">August 28, 2020</div>
          </td>
        </tr>
        <tr>
          <td style="width: 31.58%; vertical-align: top;">
            <div style="text-align: center;">Albert A. Luderer, Ph.D.</div>
          </td>
          <td style="width: 1.32%; vertical-align: middle;">
            <div>&#8203;</div>
          </td>
          <td style="width: 42.11%; vertical-align: top;">&#160;</td>
          <td style="width: 1.32%; vertical-align: middle;">
            <div>&#8203;</div>
          </td>
          <td style="width: 23.68%; vertical-align: top;">&#160;</td>
        </tr>
        <tr>
          <td style="width: 31.58%; vertical-align: top;">&#160;</td>
          <td style="width: 1.32%; vertical-align: middle;">
            <div>&#8203;</div>
          </td>
          <td style="width: 42.11%; vertical-align: top;">&#160;</td>
          <td style="width: 1.32%; vertical-align: middle;">
            <div>&#8203;</div>
          </td>
          <td style="width: 23.68%; vertical-align: top;">&#160;</td>
        </tr>
        <tr>
          <td style="width: 31.58%; vertical-align: top; border-bottom: 2px solid rgb(0, 0, 0);">
            <div style="text-align: center;">/s/ Hannah Mamuszka</div>
          </td>
          <td style="width: 1.32%; vertical-align: middle; padding-bottom: 2px;">
            <div>&#8203;</div>
          </td>
          <td style="width: 42.11%; vertical-align: top; padding-bottom: 2px;">
            <div style="text-align: center;">Director</div>
          </td>
          <td style="width: 1.32%; vertical-align: middle; padding-bottom: 2px;">
            <div>&#8203;</div>
          </td>
          <td style="width: 23.68%; vertical-align: top; padding-bottom: 2px;">
            <div style="text-align: center;">August 28, 2020</div>
          </td>
        </tr>
        <tr>
          <td style="width: 31.58%; vertical-align: top;">
            <div style="text-align: center;">Hannah Mamuszka</div>
          </td>
          <td style="width: 1.32%; vertical-align: middle;">
            <div>&#8203;</div>
          </td>
          <td style="width: 42.11%; vertical-align: top;">&#160;</td>
          <td style="width: 1.32%; vertical-align: middle;">
            <div>&#8203;</div>
          </td>
          <td style="width: 23.68%; vertical-align: top;">&#160;</td>
        </tr>
        <tr>
          <td style="width: 31.58%; vertical-align: top;">&#160;</td>
          <td style="width: 1.32%; vertical-align: middle;">
            <div>&#8203;</div>
          </td>
          <td style="width: 42.11%; vertical-align: top;">&#160;</td>
          <td style="width: 1.32%; vertical-align: middle;">
            <div>&#8203;</div>
          </td>
          <td style="width: 23.68%; vertical-align: top;">&#160;</td>
        </tr>
        <tr>
          <td style="width: 31.58%; vertical-align: top; border-bottom: 2px solid rgb(0, 0, 0);">
            <div style="text-align: center;">/s/ Christopher Twomey</div>
          </td>
          <td style="width: 1.32%; vertical-align: middle; padding-bottom: 2px;">
            <div>&#8203;</div>
          </td>
          <td style="width: 42.11%; vertical-align: top; padding-bottom: 2px;">
            <div style="text-align: center;">Director</div>
          </td>
          <td style="width: 1.32%; vertical-align: middle; padding-bottom: 2px;">
            <div>&#8203;</div>
          </td>
          <td style="width: 23.68%; vertical-align: top; padding-bottom: 2px;">
            <div style="text-align: center;">August 28, 2020</div>
          </td>
        </tr>
        <tr>
          <td style="width: 31.58%; vertical-align: top;">
            <div style="text-align: center;">Christopher Twomey</div>
          </td>
          <td style="width: 1.32%; vertical-align: middle;">
            <div>&#8203;</div>
          </td>
          <td style="width: 42.11%; vertical-align: top;">&#160;</td>
          <td style="width: 1.32%; vertical-align: middle;">
            <div>&#8203;</div>
          </td>
          <td style="width: 23.68%; vertical-align: top;">&#160;</td>
        </tr>
        <tr>
          <td style="width: 31.58%; vertical-align: top;">&#160;</td>
          <td style="width: 1.32%; vertical-align: middle;">
            <div>&#8203;</div>
          </td>
          <td style="width: 42.11%; vertical-align: top;">&#160;</td>
          <td style="width: 1.32%; vertical-align: middle;">
            <div>&#8203;</div>
          </td>
          <td style="width: 23.68%; vertical-align: top;">&#160;</td>
        </tr>
        <tr>
          <td style="width: 31.58%; vertical-align: top; border-bottom: 2px solid rgb(0, 0, 0);">
            <div style="text-align: center;">/s/ Kristiina Vuori, M.D., Ph.D.</div>
          </td>
          <td style="width: 1.32%; vertical-align: middle; padding-bottom: 2px;">
            <div>&#8203;</div>
          </td>
          <td style="width: 42.11%; vertical-align: top; padding-bottom: 2px;">
            <div style="text-align: center;">Director</div>
          </td>
          <td style="width: 1.32%; vertical-align: middle; padding-bottom: 2px;">
            <div>&#8203;</div>
          </td>
          <td style="width: 23.68%; vertical-align: top; padding-bottom: 2px;">
            <div style="text-align: center;">August 28, 2020</div>
          </td>
        </tr>
        <tr>
          <td style="width: 31.58%; vertical-align: top;">
            <div style="text-align: center;">Kristiina Vuori, M.D., Ph.D.</div>
          </td>
          <td style="width: 1.32%; vertical-align: middle;">
            <div>&#8203;</div>
          </td>
          <td style="width: 42.11%; vertical-align: top;">&#160;</td>
          <td style="width: 1.32%; vertical-align: middle;">
            <div>&#8203;</div>
          </td>
          <td style="width: 23.68%; vertical-align: top;">&#160;</td>
        </tr>

    </table>
    <div><br>
    </div>
    <div>
      <hr style="height: 2px; color: #000000; background-color: #000000; text-align: center; margin-left: auto; margin-right: auto; border: none;" align="center" noshade="noshade"></div>
  </div>
</body>
</html>
[{"type": "S-8", "sequence": "1", "filename": "nt10014149x5_s8.htm", "description": "FORM S-8", "secsgml_size_bytes": 56250}]
{"company-data": {"conformed-name": "Bionano Genomics, Inc", "cik": "0001411690", "assigned-sic": "3826", "irs-number": "261756290", "state-of-incorporation": "DE", "fiscal-year-end": "1231"}, "filing-values": {"form-type": "S-8", "act": "33", "file-number": "333-248468", "film-number": "201147915"}, "business-address": {"street1": "9540 TOWNE CENTRE DRIVE", "street2": "SUITE 100", "city": "SAN DIEGO", "state": "CA", "zip": "92121", "phone": "(858) 888-7600"}, "mail-address": {"street1": "9540 TOWNE CENTRE DRIVE", "street2": "SUITE 100", "city": "SAN DIEGO", "state": "CA", "zip": "92121"}, "former-company": [{"former-conformed-name": "BioNano Genomics, Inc", "date-changed": "20120703"}, {"former-conformed-name": "BioNanomatrix Inc", "date-changed": "20070906"}]}
As filed with the Securities and Exchange Commission
      on August 28, 2020
Registration No. 333-
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM S-8
REGISTRATION STATEMENT
UNDER
THE SECURITIES ACT OF 1933
Bionano Genomics, Inc.
(Exact name of registrant as specified in its charter)
Delaware
26-1756290
(State or other jurisdiction of
incorporation or organization)
(I.R.S. Employer
Identification No.)
9540 Towne Centre Drive, Suite 100
San Diego, California
92121
(Address of Principal Executive Offices)
(Zip Code)
Bionano Genomics, Inc. 2020 Inducement Plan
(Full titles of the plans)
R. Erik Holmlin, Ph.D.
President and Chief Executive Officer
Bionano Genomics, Inc.
9540 Towne Centre Drive, Suite 100
San Diego, California 92121
(858) 888-7600
(Name, address, including zip code, and telephone number, including area code, of agent for service)
Copies to:
Thomas A. Coll, Esq.
James C. Pennington, Esq.
Cooley LLP
4401 Eastgate Mall
San Diego, California 92121
(858) 550-6000
R. Erik Holmlin, Ph.D.
President and Chief Executive Officer
Bionano Genomics, Inc.
9540 Towne Centre Drive, Suite 100
San Diego, California 92121
(858) 888-7600
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of "large accelerated filer," "accelerated
      filer," "smaller reporting company," and "emerging growth company" in Rule 12b-2 of the Exchange Act.
Large accelerated filer ☐
Accelerated filer ☐
Non-accelerated filer ☒
Smaller reporting company ☒
Emerging growth company ☒
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the
      Securities Act. ☐
CALCULATION OF REGISTRATION FEE
Title of Securities to be Registered
Amount to be
Registered
(1)
Proposed Maximum
Offering Price per
Share
Proposed Maximum
Aggregate
Offering Price
Amount of
Registration Fee
Common Stock, par value $0.0001 per share
2,100,000
(2)
$0.63
(3)
$1,323,000
(3)
$171.73
(1)
Pursuant to Rule 416(a) under the Securities Act of 1933, as amended (the "
Securities Act
"), this Registration Statement shall also cover any additional shares of common stock,
              par value $0.0001 per share ("
Common Stock
"), of Bionano Genomics, Inc. (the "
Registrant
") that become issuable under the
              Registrant's 2020 Inducement Plan (the "
Inducement Plan
") by reason of any stock dividend, stock split, recapitalization or any other similar transaction effected without receipt of
              consideration which results in an increase in the number of outstanding shares of Common Stock.
(2)
Represents shares of Common Stock reserved for issuance under the Inducement Plan.
(3)
This estimate is made pursuant to Rule 457(h)(1) and Rule 457(c) of the Securities Act solely for purposes of calculating the registration fee. The price per share and aggregate offering price are based upon the average of the high and low
              prices of the Common Stock on August 27, 2020, as reported on the Nasdaq Capital Market.
PART I
INFORMATION REQUIRED IN THE SECTION 10(A) PROSPECTUS
The information called for by Part I of Form S-8 is omitted from this Registration Statement in accordance with Rule 428 of the Securities Act and the instructions to Form S-8. In accordance with the rules and regulations of the Securities and
      Exchange Commission (the "
Commission
") and the instructions to Form S-8, such documents are not being filed with the Commission either as part of this Registration Statement or as
      prospectuses or prospectus supplements pursuant to Rule 424.
PART II
INFORMATION REQUIRED IN THE REGISTRATION STATEMENT
ITEM 3.
INCORPORATION OF DOCUMENTS BY REFERENCE.
The following documents filed by the Registrant with the Commission are incorporated by reference into this Registration Statement:
(a)
The Registrant's Annual Report on Form 10-K for the fiscal year ended December 31, 2019 (the "
Annual Report
"), filed with the Commission on
March 10, 2020
.
(b)
the description of the Registrant's Common Stock that is contained in a registration statement on Form 8-A filed on
August 17, 2018
(File No. 001-38613) under the Securities Exchange Act of 1934, as amended (the "
Exchange

        Act
"), including any amendment or report filed for the purpose of updating such description, including Exhibit 4.16 to the Registrant's Annual Report; and
(c)
all other reports and documents subsequently filed by the Registrant pursuant to Sections 13(a), 13(c), 14 and 15(d) of the Exchange Act (other than Current Reports furnished under Item 2.02 or Item 7.01
      of Form 8-K and exhibits furnished on such form that relate to such items) on or after the date of this Registration Statement and prior to the filing of a post-effective amendment to this Registration Statement that indicates that all securities
      offered have been sold or that deregisters all securities then remaining unsold, shall be deemed to be incorporated by reference herein and to be a part of this Registration Statement from the date of the filing of such reports and documents. Any
      statement contained in a document incorporated or deemed to be incorporated by reference herein shall be deemed to be modified or superseded for purposes of this Registration Statement to the extent that a statement contained herein or in any
      subsequently filed document that also is deemed to be incorporated by reference herein modifies or supersedes such statement. Any such statement so modified or superseded shall not be deemed, except as so modified or superseded, to constitute a part
      of this Registration Statement.
ITEM 4.
DESCRIPTION OF SECURITIES.
Not applicable.
ITEM 5.
INTERESTS OF NAMED EXPERTS AND COUNSEL.
Not applicable.
ITEM 6.
INDEMNIFICATION OF DIRECTORS AND OFFICERS.
Section 145 of the Delaware General Corporation Law authorizes a court to award, or a corporation's board of directors to grant, indemnity to directors and officers in terms sufficiently broad to permit such indemnification under certain
      circumstances for liabilities, including reimbursement for expenses incurred, arising under the Securities Act. The Registrant's amended and restated certificate of incorporation that will be in effect following the closing of the initial public
      offering permits indemnification of our directors, officers and other agents to the maximum extent permitted by the Delaware General Corporation Law, and the Registrant's amended and restated bylaws that will be in effect following the closing of the
      initial public offering provide that the Registrant will indemnify its directors and executive officers and permit the Registrant to indemnify its other officers, employees and other agents, in each case to the maximum extent permitted by the
      Delaware General Corporation Law.
The Registrant has entered into indemnification agreements with its directors and officers, whereby it has agreed to indemnify its directors and officers to the fullest extent permitted by law, including indemnification against expenses and
      liabilities incurred in legal proceedings to which the director or officer was, or is threatened to be made, a party by reason of the fact that such director or officer is or was a director, officer, employee or agent of the Registrant, provided that
      such director or officer acted in good faith and in a manner that the director or officer reasonably believed to be in, or not opposed to, the best interest of the Registrant. At present, there is no pending litigation or proceeding involving a
      director or officer of the Registrant regarding which indemnification is sought, nor is the registrant aware of any threatened litigation that may result in claims for indemnification.
The Registrant maintains insurance policies that indemnify its directors and officers against various liabilities arising under the Securities Act and the Exchange Act that might be incurred by any director or officer in his or her capacity as
      such.
ITEM 7.
EXEMPTION FROM REGISTRATION CLAIMED.
Not applicable.
ITEM 8.
EXHIBITS.
Exhibit Number
Description
4.1
(1)
Amended and Restated Certificate of Incorporation of the Registrant.
4.2
(1)
Amended and Restated Bylaws of the Registrant.
4.3
(2)
Form of Common Stock Certificate of the Registrant.
5.1
Opinion of Cooley LLP.
23.1
Consent of Independent Registered Public Accounting Firm.
23.2
Consent of Cooley LLP. Reference is made to Exhibit 5.1.
24.1
Power of Attorney. Reference is made to the signature page hereto.
99.1
(3)
Bionano Genomics, Inc. 2020 Inducement Plan.
99.2
(3)
Form of Stock Option Grant Notice and Stock Option Agreement under the Bionano Genomics, Inc. 2020 Inducement Plan.
(1)
Incorporated by reference to the Registrant's Current Report on Form 8-K, filed with the SEC on August 24, 2018.
(2)
Incorporated by reference to the Registrant's Registration Statement on Form S-1 (File No. 333-225970), as amended.
(3)
Incorporated by reference to the Registrant's Current Report on Form 8-K, filed with the SEC on August 24, 2020.
ITEM 9.
UNDERTAKINGS.
A. The undersigned Registrant hereby undertakes:
(1) To file, during any period in which offers or sales are being made, a post-effective amendment to this Registration Statement:
(i) To include any prospectus required by Section 10(a)(3) of the Securities Act;
(ii) To reflect in the prospectus any facts or events arising after the effective date of the Registration Statement (or the most recent post-effective amendment thereof) which, individually or in the aggregate,
      represent a fundamental change in the information set forth in the Registration Statement. Notwithstanding the foregoing, any increase or decrease in volume of securities offered (if the total dollar value of securities offered would not exceed that
      which was registered) and any deviation from the low or high end of the estimated maximum offering range may be reflected in the form of prospectus filed with the Commission pursuant to Rule 424(b) if, in the aggregate, the changes in volume and
      price represent no more than a 20% change in the maximum aggregate offering price set forth in the "Calculation of Registration Fee" table in the effective Registration Statement; and
(iii) To include any material information with respect to the plan of distribution not previously disclosed in the Registration Statement or any material change to such information in the Registration Statement.
Provided, however
, that paragraphs (A)(1)(i) and (A)(1)(ii) do not apply if the information required to be included in a post-effective amendment by those paragraphs is contained in reports filed with or
      furnished to the Commission by the Registrant pursuant to Section 13 or Section 15(d) of the Exchange Act that are incorporated by reference in the Registration Statement.
(2) That, for the purpose of determining any liability under the Securities Act, each such post-effective amendment shall be deemed to be a new registration statement relating to the securities offered herein, and the offering of such securities
      at that time shall be deemed to be the initial bona fide offering thereof.
(3) To remove from registration by means of a post-effective amendment any of the securities being registered which remain unsold at the termination of the offering.
(4) That, for the purpose of determining liability of the Registrant under the Securities Act to any purchaser in the initial distribution of the securities, the undersigned Registrant undertakes that in a primary offering of securities of the
      undersigned Registrant pursuant to this registration statement, regardless of the underwriting method used to sell the securities to the purchaser, if the securities are offered or sold to such purchaser by means of any of the following
      communications, the undersigned Registrant will be a seller to the purchaser and will be considered to offer or sell such securities to such purchaser:
(i) Any preliminary prospectus or prospectus of the undersigned Registrant relating to the offering required to be filed pursuant to Rule 424;
(ii) Any free writing prospectus relating to the offering prepared by or on behalf of the undersigned Registrant or used or referred to by the undersigned Registrant;
(iii) The portion of any other free writing prospectus relating to the offering containing material information about the undersigned Registrant or its securities provided by or on behalf of the undersigned Registrant;
      and
(iv) Any other communication that is an offer in the offering made by the undersigned Registrant to the purchaser.
B. The undersigned Registrant hereby undertakes that, for purposes of determining any liability under the Securities Act, each filing of the Registrant's annual report pursuant to Section 13(a) or Section 15(d) of the Exchange Act (and, where
      applicable, each filing of an employee benefit plan's annual report pursuant to Section 15(d) of the Exchange Act) that is incorporated by reference in the Registration Statement shall be deemed to be a new registration statement relating to the
      securities offered herein, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof.
C. Insofar as indemnification for liabilities arising under the Securities Act may be permitted to directors, officers and controlling persons of the Registrant pursuant to the foregoing provisions, or otherwise, the Registrant has been advised
      that in the opinion of the Commission such indemnification is against public policy as expressed in the Securities Act and is, therefore, unenforceable. In the event that a claim for indemnification against such liabilities (other than the payment by
      the Registrant of expenses incurred or paid by a director, officer or controlling person of the Registrant in the successful defense of any action, suit or proceeding) is asserted by such director, officer or controlling person in connection with the
      securities being registered, the Registrant will, unless in the opinion of its counsel the matter has been settled by controlling precedent, submit to a court of appropriate jurisdiction the question whether such indemnification by it is against
      public policy as expressed in the Securities Act and will be governed by the final adjudication of such issue.
SIGNATURES
Pursuant to the requirements of the Securities Act of 1933, as amended, the Registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused this Registration Statement
      to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of San Diego, State of California, on August 28, 2020.
BIONANO GENOMICS, INC.
By:
/s/ R. Erik Holmlin, Ph.D.
R. Erik Holmlin, Ph.D.
President and Chief Executive Officer
POWER OF ATTORNEY
KNOW ALL BY THESE PRESENTS, that each person whose signature appears below constitutes and appoints R. Erik Holmlin, Ph.D. as his or her true and lawful attorney-in-fact and agent, with the full power of substitution, for him or her and in his or
      her name, place or stead, in any and all capacities, to sign any and all amendments to this Registration Statement (including post-effective amendments), and to file the same, with exhibits thereto and other documents in connection therewith, with
      the Securities and Exchange Commission, granting unto said attorney-in-fact and agent full power and authority to do and perform each and every act and thing requisite and necessary to be done in and about the premises, as fully to all intents and
      purposes as he or she might or could do in person, hereby ratifying and confirming all that said attorney-in-fact and agent, or his substitute or substitutes, may lawfully do or cause to be done by virtue hereof.
Pursuant to the requirements of the Securities Act of 1933, as amended, this Registration Statement has been signed by the following persons in the capacities and on the dates indicated.
Signature
​
Title
​
Date
​
​
/s/ R. Erik Holmlin, Ph.D.
​
Chief Executive Officer and Director
(Principal Executive and Financial Officer)
​
August 28, 2020
R. Erik Holmlin, Ph.D.
​
​
​
/s/ Mark Adamchak
​
Controller
(Principal Accounting Officer)
​
August 28, 2020
Mark Adamchak
​
​
​
/s/ David L. Barker, Ph.D.
​
Director
​
August 28, 2020
David L. Barker, Ph.D.
​
​
​
​
/s/ Yvonne Linney, Ph.D.
​
Director
​
August 28, 2020
Yvonne Linney, Ph.D.
​
​
​
​
/s/ Albert A. Luderer, Ph.D.
​
Director
​
August 28, 2020
Albert A. Luderer, Ph.D.
​
​
​
​
/s/ Hannah Mamuszka
​
Director
​
August 28, 2020
Hannah Mamuszka
​
​
​
​
/s/ Christopher Twomey
​
Director
​
August 28, 2020
Christopher Twomey
​
​
​
​
/s/ Kristiina Vuori, M.D., Ph.D.
​
Director
​
August 28, 2020
Kristiina Vuori, M.D., Ph.D.
​
​